Last reviewed · How we verify
NCT04077710
RISI in the Treatment of Recurrent Chest Wall Malignancies After EBRT
trial testing Radioactive Iodine-125 Seeds Implantation in Chest Wall Tumor in 30 participants. Status unknown.
30 April 2024
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 May 2020 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Radioactive Iodine-125 Seeds Implantation
Conditions studied
- Chest Wall Tumor — all drugs for Chest Wall Tumor →
Sponsor
Peking University Third Hospital
Who can join
Adults 18 to 80, any sex, with Chest Wall Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will observe the efficacy and toxicities of 3-dimensional printing noncoplanar template assisted CT guided radioactive iodine-125 seeds implantation in the treatment of patients with recurrent chest wall malignancies after external beam radiotherapy prospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04077710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radioactive Iodine-125 Seeds Implantation
Trials testing the same drug.
- NCT05421507 — 3D-PCT Combined With CT-guided Radioactive I-125 Seed Implantation in the Treatment of Head and Neck Tumors · recruiting
Other recruiting trials for Chest Wall Tumor
Currently open trials in the same condition.
- NCT07338006 — Chest Wall Reconstruction Cohort · NA · recruiting
- NCT03971045 — Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer · Phase 2 · recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04077710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 27 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04077710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing